Alfuzosin Prolonged-
Sponsors
Bio-innova and Synchron.Co.,Ltd
Conditions
Bioequivalence study
Bioequivalence study
Alfuzosin
Phase 1
Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Alfuzosin Prolonged-Release Tablet (10 mg) relative to Xatral(R) XL 10 mg (Original Alfuzosin Prolonged-Release Tablet (10 mg)) in healthy Thai male volunteers under fasting condition (ALF-029-19)
Active, not recruitingTCTR20200720001
Start: 2020-09-21Target: 48Updated: 2026-08-03
Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Alfuzosin Prolonged-Release Tablet (10 mg) relative to Xatral XL 10 mg (Original Alfuzosin Prolonged-Release Tablet (10 mg)) in healthy Thai male volunteers under fed condition
Active, not recruitingTCTR20201002006
Start: 2021-05-05Target: 30Updated: 2026-08-03